CA3224748A1 - Novel pharmaceutical salts and polymorphic forms of an erbb and btk inhibitor - Google Patents

Novel pharmaceutical salts and polymorphic forms of an erbb and btk inhibitor Download PDF

Info

Publication number
CA3224748A1
CA3224748A1 CA3224748A CA3224748A CA3224748A1 CA 3224748 A1 CA3224748 A1 CA 3224748A1 CA 3224748 A CA3224748 A CA 3224748A CA 3224748 A CA3224748 A CA 3224748A CA 3224748 A1 CA3224748 A1 CA 3224748A1
Authority
CA
Canada
Prior art keywords
crystalline form
compound
egfr
acid salt
xrpd pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3224748A
Other languages
English (en)
French (fr)
Inventor
Jun-Cheng Zheng
Jianan JIANG
Qinghai GUO
Shih-Ying Chang
Qingbei Zeng
Honchung TSUI
Zhenfan YANG
Xiaolin Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dizal Jiangsu Pharmaceutical Co Ltd
Original Assignee
Dizal Jiangsu Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dizal Jiangsu Pharmaceutical Co Ltd filed Critical Dizal Jiangsu Pharmaceutical Co Ltd
Publication of CA3224748A1 publication Critical patent/CA3224748A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/185—Saturated compounds having only one carboxyl group and containing keto groups
    • C07C59/225—Saturated compounds having only one carboxyl group and containing keto groups containing —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3224748A 2021-08-02 2022-07-29 Novel pharmaceutical salts and polymorphic forms of an erbb and btk inhibitor Pending CA3224748A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021110048 2021-08-02
CNPCT/CN2021/110048 2021-08-02
PCT/CN2022/109065 WO2023011358A1 (en) 2021-08-02 2022-07-29 Novel pharmaceutical salts and polymorphic forms of an erbb and btk inhibitor

Publications (1)

Publication Number Publication Date
CA3224748A1 true CA3224748A1 (en) 2023-02-09

Family

ID=85154265

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3224748A Pending CA3224748A1 (en) 2021-08-02 2022-07-29 Novel pharmaceutical salts and polymorphic forms of an erbb and btk inhibitor

Country Status (11)

Country Link
US (1) US20250197377A1 (OSRAM)
EP (1) EP4380924A4 (OSRAM)
JP (1) JP2024529533A (OSRAM)
KR (1) KR20240042640A (OSRAM)
CN (1) CN117794902A (OSRAM)
AR (1) AR126673A1 (OSRAM)
AU (1) AU2022324410A1 (OSRAM)
CA (1) CA3224748A1 (OSRAM)
MX (1) MX2024001367A (OSRAM)
TW (1) TW202321223A (OSRAM)
WO (1) WO2023011358A1 (OSRAM)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024261740A1 (en) 2023-06-23 2024-12-26 Assia Chemical Industries, Ltd. Solid state forms of sunvozertinib

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2866857C (en) * 2012-03-15 2021-03-09 Celgene Avilomics Research, Inc. Salts of an epidermal growth factor receptor kinase inhibitor
CN105384694B (zh) * 2014-08-22 2020-09-04 四川海思科制药有限公司 一种取代的氨基嘧啶衍生物及其制备方法和药物用途
CN106905245B (zh) * 2015-12-23 2021-06-25 正大天晴药业集团股份有限公司 2,4-二取代的嘧啶类化合物
CN106083736A (zh) * 2016-06-21 2016-11-09 郑州泰基鸿诺医药股份有限公司 一种嘧啶类化合物、egfr抑制剂及其应用
TWI798334B (zh) * 2018-01-31 2023-04-11 大陸商迪哲（江蘇）醫藥股份有限公司 Ｅｒｂｂ／ｂｔｋ抑制劑
WO2019177375A1 (ko) * 2018-03-13 2019-09-19 포로노이바이오 주식회사 2, 4, 5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
EP4380924A4 (en) 2025-10-01
AR126673A1 (es) 2023-11-01
TW202321223A (zh) 2023-06-01
EP4380924A1 (en) 2024-06-12
WO2023011358A1 (en) 2023-02-09
AU2022324410A1 (en) 2024-01-18
CN117794902A (zh) 2024-03-29
MX2024001367A (es) 2024-02-27
JP2024529533A (ja) 2024-08-06
KR20240042640A (ko) 2024-04-02
US20250197377A1 (en) 2025-06-19

Similar Documents

Publication Publication Date Title
CN114846006B (zh) 杂环化合物及其制备方法和用途
US12084431B2 (en) Pharmaceutical salts of pyrimidine derivatives and method of treating disorders
CN111100077A (zh) 3-(2,6-二氯-3,5-二甲氧基-苯基)-1-{6-[4-(4-乙基-哌嗪-1-基)-苯基氨基]-嘧啶-4-基}-1-甲基-脲及其盐的晶型
JP7492742B2 (ja) 置換ジアミノ複素環式カルボキサミド化合物、該化合物を含む組成物およびその使用
IL298132A (en) Salt and crystal forms of 4-amino-5-(6-(4-methylpiperazin-1-yl)-1h-benzo[d]imidazol-2-yl)thieno[2,3-b]pyridin-6(7h)-one
WO2023011358A1 (en) Novel pharmaceutical salts and polymorphic forms of an erbb and btk inhibitor
JP2025160244A (ja) １－チアゾール－２－イル－ピラゾール－５－カルボン酸誘導体の結晶多形
EP1966192B1 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
TW202311267A (zh) 咪唑烷酮類化合物的多晶型物、包含其的藥物組合物、其製備方法及其應用
JP6961348B2 (ja) 置換されたイミダゾピリジニル−アミノピリジン化合物の塩および多型
CA3217088A1 (en) Crystalline forms of (s, e)-4-(dimethylamino)-n-(3-(4-(2-hydroxy-1-phenylethylamino)-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl)but-2-enamide free base
HK40109564A (zh) Erbb和btk抑制剂的新型药用盐和多晶型形式
EP3484872B1 (en) Crystalline forms of 4-cyano-n-(2-(4,4-dimethylcyclohex-1-en-1-yl)-6-(2,2,6,6-tetramethyltetrahydro-2h-pyran-4-yl)pyridin-3-yl)-1h-imidazole-2-carboxamide
KR102965826B1 (ko) 헤테로고리 화합물, 이의 제조 방법 및 이의 용도
TW202342041A (zh) 一種藥物組合物及所含活性成分化合物的製備方法
HK40126640A (zh) 喹唑啉erbb抑制剂的药物形式
HK40072166B (zh) 杂环化合物及其制备方法和用途
TW202446386A (zh) 喹唑啉ＥｒｂＢ抑制劑的藥物形式
HK40096550A (en) Pharmaceutical salts of pyrimidine derivatives and method of treating disorders
KR20210050530A (ko) 신규 아자트리시클릭 화합물의 염 형태 및 결정 형태 및 그의 용도
HK40058867B (zh) 咪唑幷吡啶基化合物及其用於治疗增生性疾病的用途
CN108383799A (zh) 抗肿瘤新药的合成方法及其药用盐和固体制剂

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250708

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250708